摘要:
A purified protein derived from Leishmania donovani , for use as antigen in an assay for the determination of Leishmaniasis and for use in vaccines against this disease. Such proteins react with monoclonal antibodies raised against Leishmania donovani . Identical or equivalent proteins can be produced by recombinant DNA technology. Instead of the proteins there can also be used effective segments thereof.
摘要:
The invention relates to hybridomas producing anti-Leishmania monoclonal antibodies which are characterized by their capacity to inhibit the infection of sarcomateous cells by the promastigote forms of one or a plurality of Leishmania species when those sarcomateous cells are contacted with said promastigote forms pre-incubated with the monoclonal antibodies under conditions which, in the absence of said monoclonal antibodies, would result in a high parasitemy in said cells. These monoclonal antibodies and the proteins of parasites which they recognize may be used in operations for detecting leishmanioses.
摘要:
Es wird ein Impfstoff gegen Parasitosen wie Leishmaniasis beschrieben, der als Wirkstoff wenigstens ein Membranantigen des Parasiten in die Lipiddoppelschicht von Liposomen inkorporiert enthält, das einen Schutz gegen Infektion mit dem homologen Parasiten hervorruft. Als Membran-Antigen wird z. B. das Glykoprotein gp63 oder das Glykolipid EF verwendet.
摘要:
The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus.
摘要:
The present invention provides vectors that contain and express in vivo or in vitro sand fly Lu. longipalpis salivary antigens that elicit an immune response in animal or human against Leishmania, vaccine compositions comprising said vectors and/or Lu. longipalpis salivary polypeptides, methods of vaccination against Leishmania, and kits for use with such methods and compositions.